Key Highlights

  • FY26 sales reached a record USD 2.14 billion.
  • Adjusted Earnings Per Share increased 17.8% to USD 1.486.
  • Healthcare and Industrial both delivered reported sales growth.
  • Currency, input costs, integration and industrial Demand remain important risks.

Ansell Limited (ASX: ANN) does not generate headlines the way a lithium explorer or a Fintech disruptor might, but the maker of protective gloves, industrial safety equipment and single-use medical products has quietly turned in one of the more solid full-year results on the ASX this reporting season. For the twelve months to 30 June 2026, the company reported record sales of USD 2.140 billion, alongside adjusted earnings per share of US148.6 cents, up 17.8% on the prior year.

That combination of record top-line and double-digit bottom-line growth, delivered by a Business selling into industrial, healthcare and life sciences markets across dozens of countries, is precisely the kind of unglamorous consistency that income and defensive-growth investors tend to prize — provided it continues.

What Has Happened?

Ansell's FY26 result showed broad-based growth across both of its major divisions. The Healthcare segment, which includes surgical and examination gloves along with life sciences products, generated sales of USD 1.193 billion, up 8.0% on a reported basis, with the Cleanroom product category growing 10.0% on an adjusted basis. The Industrial segment, covering safety gloves and protective clothing sold into manufacturing, construction, oil and gas and other heavy industries, contributed sales of USD 947.3 million, up 5.4%.

Profitability improved faster than revenue. Adjusted earnings before interest and tax reached USD 321.9 million, an increase of 14.1%, lifting the adjusted EBIT Margin to 15.0%. Management attributed the margin expansion to a deliberate mix shift toward higher-value end markets, alongside pricing and sourcing actions that offset cost Inflation and the impact of US tariffs on imported goods — a reminder that even a company without direct exposure to volatile Commodity prices still has to actively manage input costs and trade policy risk in a global Supply chain business.

Cash generation was a standout feature of the result. Operating Cash Flow surged 156.3% to USD 270.1 million, and the company used part of that cash to reduce net Debt by USD 52.3 million over the year, strengthening the Balance Sheet heading into FY27.

What the Numbers Show on Dividends and Capital Returns

Ansell reports and pays its dividends in US dollars, reflecting the global nature of its earnings base, which is a detail Australian investors sometimes overlook when comparing headline Yield figures across the ASX. The board declared a final Dividend of US41.5 cents per share, unfranked, taking the full-year dividend to US68.1 cents, an increase of roughly 23% on the prior year — a growth rate that lines up closely with screener data referencing dividend-per-share growth of about 23% ahead of this article, even though that data appeared to quote the distribution in Australian dollar terms rather than the US dollar figure the company actually declares. Investors relying on third-party screeners for Ansell's yield should be aware of this currency distinction, since converting US dollar dividends to Australian dollars at the prevailing Exchange Rate is necessary to arrive at a like-for-like yield on the ASX-quoted share price.

Beyond the dividend, Ansell completed USD 118.4 million of share buy-backs during FY26 and has flagged a further USD 200 million buy-back programme to run through FY27, underscoring management's preference for returning surplus capital to shareholders in a business that does not currently appear to need heavy reinvestment to sustain growth.

Why Investors Are Watching

Ansell's appeal to more defensively minded investors rests on the non-discretionary nature of much of its product range. Surgical gloves, examination gloves and industrial safety equipment are consumables that hospitals, laboratories and factories need to keep buying regardless of the broader economic cycle, which gives the business a degree of earnings resilience that more cyclical industrials typically lack. That said, Ansell is not immune to the cycle entirely — industrial demand can soften when Manufacturing activity slows, and healthcare volumes can be affected by hospital capital budgets and destocking cycles further down the supply chain, both of which have weighed on results in prior years.

For FY27, management guided to adjusted earnings per share of US158 cents to US170 cents, implying continued double-digit growth at the midpoint relative to FY26's US148.6 cents. As with any company guidance, this reflects management's current expectations rather than a guaranteed outcome, and is subject to the same input cost, currency and demand variables that shaped the FY26 result.

The Bigger Industry Picture

The global personal protective equipment industry has settled into a more normal demand pattern in the years since the extraordinary pandemic-era spike and subsequent destocking cycle that whipsawed glove manufacturers' earnings between 2020 and 2023. Ansell's more recent results suggest the business has worked through that distortion and returned to a steadier growth trajectory built on genuine end-market demand rather than Pandemic stockpiling. Competition remains intense, particularly from lower-cost Asian glove manufacturers in commoditised product categories, which is one reason Ansell's strategic emphasis on higher-value, more differentiated products is central to its margin story.

Key Risks

Currency movements are a persistent risk given Ansell's global Revenue base and US dollar reporting currency, which can create translation effects when results are converted for Australian investors. Trade policy, particularly US tariffs on imported protective equipment, is another live risk that management has so far managed through pricing and sourcing adjustments, but which could intensify. Competitive pressure from lower-cost manufacturers in commoditised glove categories remains a structural feature of the industry. Finally, any slowdown in industrial production globally, or destocking in the healthcare and life sciences supply chain, could weigh on volumes even if underlying end-user demand remains intact.

What Could Drive the Stock Next?

Investors will be watching whether Ansell can sustain the margin expansion seen in FY26 into the new financial year, progress against its FY27 EPS guidance range, and the pace of buy-back execution under the newly expanded programme. Broader industrial production trends across Ansell's key markets in North America, Europe and Asia, along with any further escalation or easing of Tariff policy, are likely to remain the key swing factors shaping sentiment toward the stock over the coming year.